Cloning woolly mammoths is cool. Can it be profitable?

Colossal, the biotech startup working on de-extincting the woolly mammoth and the dodo, thinks it can make trillions of dollars — almost none of it from consumer-facing products. Liz and Rohan dive into it all with CEO Ben Lamm, who has already spun out four businesses as he’s built the bioscience business with a focus on serving governments and nations looking to build drought-resistant plants, plastic-munching microbes, and much more (some of it classified!) This season of Compound Interest is in partnership with Amazon Business. Amazon Business is a trusted partner that transforms business buying by combining Amazon's vast selection, competitive pricing, and fast delivery with added tools and insights to help businesses simplify purchasing, manage spend, and buy smarter.